Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086203
Status:
COMPLETED
Last Update Posted:
2015-03-25
First Post:
2004-06-28
Brief Title:
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia CLL
Sponsor:
Point Therapeutics
Organization:
FDA Office of Orphan Products Development
Organization Data
Organization:
FDA Office of Orphan Products Development
Class:
FED
Study ID:
PTH-203
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Point Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None